BioMarin Pharmaceutical Inc
XMUN:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioMarin Pharmaceutical Inc
XMUN:BM8
|
US |
|
New Oriental Education & Technology Group Inc
NYSE:EDU
|
CN |
|
NGK Spark Plug Co Ltd
OTC:NGKSF
|
JP |
|
Rio Tinto Ltd
OTC:RTNTF
|
AU |
|
Daimler Truck Holding AG
F:DTG1
|
DE |
|
Mitsubishi UFJ Financial Group Inc
TSE:8306
|
JP |
|
PhosAgro PAO
MOEX:PHOR
|
RU |
|
A
|
APR Co Ltd
KRX:278470
|
KR |
|
B
|
Broadcom Inc
XHAN:1YD
|
US |
|
D
|
Dollar General Corp
LSE:0IC7
|
US |
|
N
|
Northern Trust Corp
F:NT4
|
US |
|
Medallion Financial Corp
NASDAQ:MFIN
|
US |
|
H
|
Home Depot Inc
XETRA:HDI
|
US |
|
Aditya Birla Capital Ltd
BSE:540691
|
IN |
|
P
|
Persimmon PLC
OTC:PSMMF
|
UK |
|
Datatec Ltd
OTC:DTTLF
|
ZA |
|
P
|
Prologis Inc
BMV:PLD
|
US |
|
N
|
New York Times Co
F:NYT
|
US |
|
M
|
Micron Technology Inc
BMV:MU
|
US |
|
H
|
Halma PLC
DUS:H11
|
UK |
|
P
|
Prudential PLC
DUS:PRU
|
HK |
|
O
|
Opendoor Technologies Inc
F:25M
|
US |
|
N
|
Nissan Chemical Corp
DUS:NSC
|
JP |
|
B
|
Beiersdorf AG
F:BEIA
|
DE |
BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical makes prescription medicines for rare genetic diseases, especially conditions that affect children and often need lifelong treatment. Its products include enzyme replacement therapies, biologic drugs, and gene therapies designed to treat the underlying cause of certain inherited disorders rather than just easing symptoms. The company sells mainly to hospitals, specialty pharmacies, and doctors who treat patients with these rare conditions. It earns money by selling these treatments, usually through highly specialized drug distribution channels and reimbursement from insurers and government health programs. Because its medicines target small patient groups, BioMarin depends on deep expertise in rare-disease research, regulatory approval, and patient support. What makes BioMarin different is its focus on a narrow set of hard-to-treat diseases where few other drug makers compete directly. It is part of the orphan-drug industry, where success comes from finding patients, proving strong clinical benefit, and building trusted relationships with specialists and payers. This gives the company a business model centered on specialized science and long-term treatment demand rather than broad-volume drug sales.
BioMarin Pharmaceutical makes prescription medicines for rare genetic diseases, especially conditions that affect children and often need lifelong treatment. Its products include enzyme replacement therapies, biologic drugs, and gene therapies designed to treat the underlying cause of certain inherited disorders rather than just easing symptoms.
The company sells mainly to hospitals, specialty pharmacies, and doctors who treat patients with these rare conditions. It earns money by selling these treatments, usually through highly specialized drug distribution channels and reimbursement from insurers and government health programs. Because its medicines target small patient groups, BioMarin depends on deep expertise in rare-disease research, regulatory approval, and patient support.
What makes BioMarin different is its focus on a narrow set of hard-to-treat diseases where few other drug makers compete directly. It is part of the orphan-drug industry, where success comes from finding patients, proving strong clinical benefit, and building trusted relationships with specialists and payers. This gives the company a business model centered on specialized science and long-term treatment demand rather than broad-volume drug sales.
Revenue: BioMarin said second quarter revenue reached nearly $1 billion, up 20% year over year, helped by a more diversified portfolio and the first full contributions from the Amicus deal.
Guidance: Management raised full-year 2026 guidance for total revenue, VOXZOGO revenue, and non-GAAP diluted EPS on the strength of first-half results and a stronger second half outlook.
VOXZOGO: VOXZOGO grew 14% year over year in the quarter, and management said the product is on track to become BioMarin’s first $1 billion franchise despite a new competitor in the U.S.
Amicus Deal: BioMarin said the Amicus acquisition is integrating well and now carries combined peak revenue potential of $2.6 billion, with about $220 million in annual cost synergies expected in 2028.
Pipeline: The company filed VOXZOGO’s sNDA for hypochondroplasia and said Phase III data for BMN 820 are expected in 2028, while BMN 333 enrollment is active globally.
Competition: Management said VOXZOGO switching has been limited so far, with around 90% of U.S. children still on therapy as of the end of July based on the company’s data.